معرفی
Michael Dickstein is an Associate Professor of Economics at New York University's Leonard N. Stern School of Business, where he has been a faculty member since 2015. He holds a Ph.D. in Business Economics from Harvard University and a B.S. in Applied Economics from Cornell University. He previously served as an Assistant Professor at Stanford University and was a Postdoctoral Associate at the Cowles Foundation, Yale University.
- Ph.D., Business Economics — Harvard University
- B.S., Applied Economics — Cornell University
His research focuses on health economics and industrial organization, particularly the economic structure of healthcare markets, insurance design, physician behavior, and pharmaceutical adoption. He employs advanced econometric and modeling tools to analyze complex market dynamics such as adverse selection, imperfect competition, and regulatory impacts. His recent work explores the macroeconomic implications of new weight-loss drugs, the design of health insurance markets under the Affordable Care Act, and Medicare payment policies.
The trends in his recent publications reveal a strong emphasis on empirical health economics, with recurring themes in market design, insurance regulation, and the economic consequences of medical innovations. His work combines theoretical modeling with real-world data to inform public policy and healthcare management.
- Best 40-under-40 MBA Professor, Poets and Quants (2021)
Professor Dickstein teaches healthcare economics in both full-time and part-time MBA programs, as well as in the undergraduate curriculum. He is a Research Associate at the National Bureau of Economic Research (NBER) and serves as Academic Director of NYU Stern’s Healthcare Initiative, where he leads interdisciplinary research on healthcare innovation and policy. He has advised on government regulations, pricing mechanisms, and insurance enrollment, and his insights are frequently sought by media outlets on pressing health and economic issues.
He is actively engaged in ongoing research on the long-term fiscal effects of new medical treatments, the dynamics of patient and physician decision-making, and the future of healthcare financing in the U.S.
